934568-25-9Relevant academic research and scientific papers
SUBSTITUTED QUINOXALINE DERIVATIVES
-
Page/Page column 195, (2016/12/01)
The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
SUBSTITUTED QUINOXALINE DERIVATIVES
-
Page/Page column 121; 122, (2016/11/28)
The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects
Papillon, Julien P. N.,Lou, Changgang,Singh, Alok K.,Adams, Christopher M.,Ksander, Gary M.,Beil, Michael E.,Chen, Wei,Leung-Chu, Jennifer,Fu, Fumin,Gan, Lu,Hu, Chii-Whei,Jeng, Arco Y.,Lasala, Daniel,Liang, Guiqing,Rigel, Dean F.,Russell, Kerry S.,Vest, John A.,Watson, Catherine
, p. 9382 - 9394 (2015/12/23)
Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor 8.
ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS
-
Page/Page column 101-102, (2012/04/23)
The present invention provides a compound of Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
